<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196689</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00021</org_study_id>
    <nct_id>NCT01196689</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics in Adolescents</brief_title>
  <acronym>PEAK</acronym>
  <official_title>An Open, Single Centre, Phase I Study in Male Adolescents With Asthma, Aged 12 to 17 Years, to Assess Pharmacokinetics of Orally Administered AZD1981 Tablets 100 mg Twice Daily for 61/2 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study pharmacokinetics in adolescents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open, single centre, phase I study in male adolescents with asthma, aged 12 to 17 years,
      to assess pharmacokinetics of orally administered AZD1981 tablets 100 mg twice daily for 61/2
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>0 hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>0.5, hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>1 hour after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>3 hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>4 hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>6 hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>8 hours after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary steady-state outcome variables to assess systemic exposure and oral clearance will be AUCτ, Css,max, Css,trough, and CL/F of AZD1981</measure>
    <time_frame>12 hours after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety assessed by adverse events</measure>
    <time_frame>During 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by Forced Expiratory Volume (FEV) in one second and Asthma Control Questionnaire</measure>
    <time_frame>Day 1 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 100 mg twice daily for 6 ½ days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981 100 mg twice daily for 61/2 days</intervention_name>
    <description>100 mg tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  A minimum of 6 months documented history of asthma

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to Visit 1
             (pre-entry)

        Exclusion Criteria:

          -  Any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the patient at risk because of participation in the
             study, or influence the result of the study, or the patient's ability to participate

          -  Any clinically relevant abnormal findings in phys.examination, clinical chemistry,
             haematology, urinalysis, vital signs, or ECG at baseline which, in the opinion of the
             investigator, may put the patient at risk because of his participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultquist</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>March 4, 2011</last_update_submitted>
  <last_update_submitted_qc>March 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Science Director (MSD)</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Pharmacokinetics AZD1981</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

